Literature DB >> 22385110

Body composition, bone mineral density and fractures in late postmenopausal women with polycystic ovary syndrome - a long-term follow-up study.

Johanna Schmidt1, Eva Dahlgren, Mats Brännström, Kerstin Landin-Wilhelmsen.   

Abstract

OBJECTIVE: Hyperandrogenism is one of the characteristic features of the polycystic ovary syndrome (PCOS). Androgens are important for bone mass. Studies on bone mineral density (BMD) and fractures in postmenopausal women with PCOS are lacking. The aim of this study was to investigate whether postmenopausal women with PCOS differ from controls regarding body composition, BMD and prevalence of fractures, and to compare women with PCOS with controls regarding correlations between total BMD and sex hormones.
DESIGN: A prospective 21-year follow-up study. Anthropometry, hormonal measurements and questionnaires were performed in 1987 and in 2008. Fractures were X-ray-verified. BMD measurements were taken in 1992, using single-photon absorptiometry (SPA), and in 2008, using dual-energy X-ray absorptiometry (DXA), to also enable measurements of body composition. PATIENTS: Twenty-five women with PCOS (Rotterdam criteria), aged 61-78 years, and 68 randomly allocated age-matched controls. MEASUREMENTS: Body composition, BMD, fractures and sex steroids.
RESULTS: At follow-up, the postmenopausal women with PCOS maintained a higher free androgen index (FAI), but had similar body fat, lean mass and BMD compared with controls. The hip circumference increased only in women with PCOS (P < 0·01), during follow-up. The fracture incidence was similar to that of controls (56% vs 41%, ns). In the controls, total BMD was positively correlated with oestradiol (R = 0·322, P < 0·01) and FAI (R = 0·307, P < 0·05) and negatively correlated with SHBG (R = -0·429, P < 0·001), but not in the women with PCOS.
CONCLUSIONS: Postmenopausal women with PCOS with persistently higher FAI had similar muscle mass, BMD and fracture incidence as controls during this long-term follow-up.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22385110     DOI: 10.1111/j.1365-2265.2012.04378.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

1.  Increased risk of fractures in patients with polycystic ovary syndrome: a nationwide population-based retrospective cohort study.

Authors:  Hsin-Yi Yang; Herng-Sheng Lee; Wan-Ting Huang; Ming-Jer Chen; Solomon Chih-Cheng Chen; Yueh-Han Hsu
Journal:  J Bone Miner Metab       Date:  2017-12-26       Impact factor: 2.626

2.  Osteosarcopenia in Reproductive-Aged Women with Polycystic Ovary Syndrome: A Multicenter Case-Control Study.

Authors:  Maryam Kazemi; Brittany Y Jarrett; Stephen A Parry; Anna E Thalacker-Mercer; Kathleen M Hoeger; Steven D Spandorfer; Marla E Lujan
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

Review 3.  Estrogens and Androgens in Skeletal Physiology and Pathophysiology.

Authors:  Maria Almeida; Michaël R Laurent; Vanessa Dubois; Frank Claessens; Charles A O'Brien; Roger Bouillon; Dirk Vanderschueren; Stavros C Manolagas
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

4.  Association of plasma GDF-9 or GDF-15 levels with bone parameters in polycystic ovary syndrome.

Authors:  Zehra Berberoglu; Aynur Aktas; Yasemin Fidan; Ayse Canan Yazici; Yalcin Aral
Journal:  J Bone Miner Metab       Date:  2014-01-16       Impact factor: 2.626

5.  Steroidal contraceptive use is associated with lower bone mineral density in polycystic ovary syndrome.

Authors:  Lisa J Moran; R L Thomson; J D Buckley; M Noakes; P M Clifton; R J Norman; G D Brinkworth
Journal:  Endocrine       Date:  2015-05-10       Impact factor: 3.633

6.  Competing Factors Link to Bone Health in Polycystic Ovary Syndrome: Chronic Low-Grade Inflammation Takes a Toll.

Authors:  Shirin Kalyan; Millan S Patel; Elaine Kingwell; Hélène C F Côté; Danmei Liu; Jerilynn C Prior
Journal:  Sci Rep       Date:  2017-06-13       Impact factor: 4.379

7.  Plasma sclerostin levels are associated with nutritional status and insulin resistance but not hormonal disturbances in women with polycystic ovary syndrome.

Authors:  Katarzyna Wyskida; Grzegorz Franik; Aleksander Jerzy Owczarek; Piotr Choręza; Piotr Kocełak; Paweł Madej; Jerzy Chudek; Magdalena Olszanecka-Glinianowicz
Journal:  Arch Gynecol Obstet       Date:  2020-06-26       Impact factor: 2.344

8.  High androgen levels protect against hypothyroidism.

Authors:  Johanna Schmidt; Eva Dahlgren; Inger Bryman; Kerstin Berntorp; Penelope Trimpou; Lars Wilhelmsen; Kerstin Landin-Wilhelmsen
Journal:  Acta Obstet Gynecol Scand       Date:  2016-12-09       Impact factor: 3.636

9.  Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution.

Authors:  M Forslund; K Landin-Wilhelmsen; P Trimpou; J Schmidt; M Brännström; E Dahlgren
Journal:  Hum Reprod Open       Date:  2020-01-15

10.  Imaging-Based Body Fat Distribution in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Shiqin Zhu; Zeyan Li; Cuiping Hu; Fengxuan Sun; Chunling Wang; Haitao Yuan; Yan Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-09       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.